Partial federal government shutdown
HCA does not anticipate any immediate impacts to our services or disruption to provider payments at this time. We will continue to monitor the situation and share updates if anything changes.
Stem cell therapy for musculoskeletal conditions
Stem cells are the basis of all tissues and organs in the body. Tissue specific (adult, somatic) stem cells have been most commonly described related to the treatment of musculoskeletal pain conditions. Stem cell therapy for joint pain is an outpatient procedure that begins with collection of stem cells from a patient (autologous) or from another person (allogeneic). The cells may be cultured or concentrated and then injected into the affected area.
Status: Decision completed
Why is stem cell therapy being reviewed?
The topic is proposed based on concerns related to the safety, efficacy, and value for stem cell injections for musculoskeletal pain.
Primary criteria ranking
- Safety = High
- Efficacy = High
- Cost = High
Documentation
| Type | Materials |
|---|---|
| Assessment (2020) |
Assessment timeline
- Draft key questions published: September 19, 2019
- Public comment period: September 19 to October 2, 2019
- Final key questions published: October 18, 2019
- Draft report published: December 31, 2019
- Public comment period: December 31 to January 29, 2019
- Final report published: February 19, 2020
- HTCC public meeting: June 12, 2020